← All trials
NCT07091370
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 27, 2025
- Primary completion
- Sep 30, 2026
- Completion date
- Mar 30, 2028
- First posted
- Jul 29, 2025
- Last posted
- Sep 22, 2025
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Juventas Therapeutics, Inc.Lead sponsor
- China Academy of Chinese Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.